Independent formulation laboratory focused on designing effective formulas to enhance cognitive and mental performance that are backed by clinical studies. We develop proprietary blends that contain powerful nootropic plant compounds that optimize functioning of the brain, mind, body, and behavior.
We research plant compounds and traditional herbal medicines that have scientific studies backing their effectiveness that impact on the brain, mind, body, and behavior – the psychopharmacology of herbal medicine and its effect on mental functioning and the nervous system by conducting modern scientific research of plant compounds and testing their effects on attention, concentration, learning, memory, language, perception, execution functions, emotion, and personality. The research is primarily focused on cannabis, stimulant plants, cognitive enhancers, herbal sedatives, anxiolytics, psychotherapeutic herbs, analgesic and anesthetic plants.
Science
Developing a phytocannabinoid
treatment for ADHD
The first step our science team did was review thousands of clinical research studies to decide what should go into our formulas and create standards of quality and efficacy. Please read below some of the studies that inspired us.
Preliminary clinical studies show the potential of phytocannabinoids as a pharmacological treatment for the main symptoms of ADHD. The link between the endocannabinoid system in relation to ADHD is not new, it comes from previous preclinical models. There are a number of psychiatrists in the U.S. that prescribe cannabis for ADHD. Also, many adults show preference to treating their ADHD with cannabis over traditional medications.
Even though more clinical research is required to establish dosing of phytocannabinoids for ADHD as they can vary drastically between different patients with attention deficit disorder; many researchers have concluded that “for adult patients with ADHD, who experience side effects or do not profit from standard medication, cannabis may be an effective and well-tolerated alternative.”
Due to the complexity of phytocannabinoids and their interactions with the Endocannabinoid system and the individuals genetic, mental, and physical differences adjusting dosing can be challenging. We recommend that when titrating and self-experimenting: start in low doses and go slow. Track and monitor your dosage, onset, duration, and effects.
This study shows that ADHD involves multiple genetic and environmental factors. Studies have found a strong relationship between the cannabinoid receptor gene and ADHD making a number of researchers believe that phytocannabinoids can lead to an enhanced related performance.
Researchers of this particular study in Germany had similar conclusions to that of Dr. Lester Grinspoon, a Harvard psychiatry professor, an astute scientific observer, and a close friend of Carl Sagan was a leading advocate for the decriminalization of marijuana. In his books, Marijuana Reconsidered and Marihuana, the Forbidden Medicine also reported the use of positive impact of cannabis for attention deficit disorder. Grinspoon described his experiences with cannabis using a disguised identity. He also believed Carl Sagan’s use of cannabis was a dramatic disconfirmation of the popular perception that cannabis diminishes motivation, “He (Sagan) was certainly highly motivated to work, to contribute.”
In a demographic survey of 4,117 patients in California who applied for medical cannabis between 2001-2007, stated that “a significant percentage of male applicants under 30 had been treated or evaluated for treatment with Ritalin or other stimulants for attention deficit hyperactivity disorder (ADHD) as children and their histories of a preference for morning use of minimal amounts (of cannabis) strongly suggest that inhaled cannabis enhances their ability to concentrate.”
Illegal cannabis cultivators reported in a six-country survey that ADHD was the fifth (15.3% n=2,070) most commonly reported medical reason to grow cannabis, the top most common were depression, anxiety, and chronic pain. The survey reported that “Scandinavian growers seem to use cannabis for the treatment of ADHD more often than growers in other countries.” In Norway, this study with 100 (illegal) cannabis users, reported that “alleviating ADHD symptoms was the most common medical motive”
Another preliminary study showed evidence that adults with ADHD may represent a subset who experience amelioration of symptoms and no cognitive impairment. The study tested individuals with ADHD using a trial cannabinoid medication. The participants were evaluated by symptoms and IQ performance. The study showed that the compound was associated with a significant improvement in hyperactivity/impulsivity and improvement for inattention.
Cannabinoids have shown positive impact in other therapeutic treatment of various anxiety-related mental health disorders like PTSD, ASD, substance addiction, etc. However, this study shows the increased the risk of substance abuse disorders in adults with ADHD. Therefore, we recommended moderated usage of the product as heavy and persistent use of cannabinoids can result in impairment in memory and attention. It is also recommended that the individual makes lifestyle adjustments and behavioral training in conjunction with product usage. We also recommend talking to a doctor prior to using cannabinoids.
Background
Generation Adderall
The New York Times Magazine’s article coined the term “Generation Adderall” for millennials. As Adderall has grown in popularity in recent years and has become the drug of choice for millennials for an energy and concentration boost at work to alertness for a night out.
Adderall, a prescription stimulant, is a mixture of amphetamine salts which are highly regulated in the United States. According to the CCHR, in 2013-14 there were approximately 5mm people in the USA taking Adderall.
According to Addiction Center, in 2012, roughly 16 million Adderall prescriptions were written for individuals between ages 20 and 39. That same year, around 116,000 people where trying to quit and get off it. While many people do suffer from ADD/ADHD and rely on it for medical mental reasons – Adderall is overprescribed and abused and a black market for it is growing.
ADHD treatment with cannabinoids is new which a number of studies already are showing its benefits, in the Cannabis Health Index (CHI) – an evidence-based scoring system – it scored in the possible to probable range of efficacy. To learn more about CHI scores, you can also visit cannabishealthindex.com
Dr. David Bearman, author of Cannabis Medicine – A Guide to the Practice of Cannabinoid Medication – is a major figure in the field and has done extensive research in studying the relationship between the cannabinoid system & ADHD and discovered the therapeutic value of cannabinoids with the brain’s dopamine systems.
“Cannabis appears to treat ADD and ADHD by increasing the availability of dopamine,” Bearman states. “This then has the same effect but is a different mechanism of action than stimulants like Ritalin (methylphenidate) and Dexedrine amphetamine, which act by binding the dopamine and interfering with the metabolic breakdown of dopamine…the most accepted theory of ADHD rests on the fact that about 70 percent of the brain’s function is to regulate input to the other 30 percent…basically the brain is overwhelmed with too much information coming too fast. In ADHD, the brain is cluttered with and too aware of all the nuances of a person’s daily experience.” – Dr. David Bearman